Test Catalog

Test ID: HL57V    
HLA-B*57:01 Genotype, Pharmacogenomics

Useful For Suggests clinical disorders or settings where the test may be helpful

Identifying individuals with an increased risk of hypersensitivity reactions to abacavir, based on the presence of the human leukocyte antigen HLA-B*57:01 allele

 

Identifying individuals taking pazopanib who have an increased risk of elevated alanine aminotransferase (ALT) levels based of the presence of the human leukocyte antigen HLA-B*57:01 allele

Testing Algorithm Delineates situations when tests are added to the initial order. This includes reflex and additional tests.

See Abacavir Hypersensitivity Testing and Initial Patient Management Algorithm in Special Instructions.

 

For additional information regarding pharmacogenomic genes and their associated drugs, see the Pharmacogenomic Associations Tables in Special Instructions.

Special Instructions Library of PDFs including pertinent information and forms related to the test

Method Name A short description of the method used to perform the test

Qualitative Allele-Specific Real-Time Polymerase Chain Reaction (PCR)

NY State Available Indicates the status of NY State approval and if the test is orderable for NY State clients.

Yes

Reporting Name Lists a shorter or abbreviated version of the Published Name for a test

HLA-B 5701 Genotype, PGx

Aliases Lists additional common names for a test, as an aid in searching

Abacavir Hypersensitivity
Elevated liver function tests
HLA B
HLA B57
HLA B5701
HLA-B57
HLA-B5701
HLAB
HLAB5701
Pazopanib
Pazopanib hepatotoxocity
Pazopanib induced elevated serum transaminases
Pazopanib liver toxicity